Jeong Won Hong

Title: Jeong Won Hong: Innovator in Antibody Research

Introduction

Jeong Won Hong is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of antibody research, particularly in the treatment of diseases related to myeloid-derived suppressor cells. With a total of 3 patents, his work has the potential to impact various medical applications.

Latest Patents

One of his latest patents focuses on the use of antibodies for preventing and treating myeloid-derived suppressor cell-related diseases. This invention relates to an antibody or an antigen-binding fragment that specifically binds to CD66c, which is expressed in myeloid-derived suppressor cells (MDSC). The anti-CD66c antibody can be effectively used for the treatment of various diseases by targeting MDSC, which can induce immunosuppression. Another notable patent involves an antibody that recognizes and binds to carbonic anhydrase. This invention includes a nucleic acid molecule coding for the antibody, a vector carrying the nucleic acid molecule, and a host cell that includes the nucleic acid molecule or the vector. The use of this antibody or its antigen-binding fragment is aimed at alleviating, preventing, treating, or diagnosing solid cancers.

Career Highlights

Throughout his career, Jeong Won Hong has worked with several notable companies, including Aprogen Medicines Inc. and Kumho HT, Inc. His experience in these organizations has contributed to his expertise in the field of antibody research and development.

Collaborations

Jeong Won Hong has collaborated with various professionals in his field, including Sangsoon Yoon and Yoo Ri Moon. These collaborations have likely enhanced his research and innovation capabilities.

Conclusion

Jeong Won Hong is a distinguished inventor whose work in antibody research holds promise for advancing medical treatments. His innovative patents and collaborations reflect his commitment to improving healthcare through scientific discovery.